Pfizer Ordered to Pay $142.1 Million in `Off-Label' Marketing Case

Bloomberg News reports that Pfizer will pay triple damages totaling $142.1 million for marketing practices of its epilepsy drug, Neurontin, found to be in violation of U.S. racketeering laws.

"U.S. District Judge Patti Saris in Boston yesterday upheld a jury’s finding that Kaiser Foundation Health Plan Inc. and Kaiser Foundation Hospitals deserved the award over the companies’ claims that Pfizer illegally promoted Neurontin for unapproved uses. Saris tripled the jury’s award of $47.3 million under a provision of the Racketeer Influenced and Corrupt Organizations Act of 1970."

See the full article: Pfizer Ordered to Pay $142.1 Million Over Neurontin `Off-Label' Marketing on Bloomberg.com.